Novartis Ag (NVS) Debt to Equity (2015 - 2025)

Novartis Ag (NVS) has 10 years of Debt to Equity data on file, last reported at $0.62 in Q4 2025.

• Quarterly Debt to Equity rose 24.87% year-over-year to $0.62 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $0.62 (up 24.87% YoY) and the FY2025 annual result came in at $0.62, up 24.87% from the prior year.
• Debt to Equity climbed to $0.62 in Q4 2025 per NVS's latest filing, from $0.5 in the prior quarter.
• The five-year high for Debt to Equity was $0.62 in Q4 2025, with the low at $0.41 in Q4 2023.
• Average Debt to Equity over 5 years is $0.48, with a median of $0.44 recorded in 2022.
• Year-over-year, Debt to Equity jumped 102.14% in 2021 and fell 7.44% in 2023.
• Novartis Ag's Debt to Equity stood at $0.43 in 2021, then rose by 2.32% to $0.44 in 2022, then decreased by 7.44% to $0.41 in 2023, then grew by 22.33% to $0.5 in 2024, then grew by 24.87% to $0.62 in 2025.
• Business Quant data shows NVS's Debt to Equity at $0.62 in Q4 2025, $0.5 in Q4 2024, and $0.41 in Q4 2023.